Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | BRAF | P15056 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10833456 | 0.91 | LMNA (0.56) | MAPTRAB9ANPC1SMN1; SMN2EPHX2 | |
| SCHEMBL10561011 | 0.89 | LMNA (0.43) | MAPTRAB9ANPC1SMN1; SMN2EPHX2 | |
| SCHEMBL10560087 | 0.89 | ALDH1A1 (0.54) | MAPTRAB9ANPC1SMN1; SMN2EPHX2 | |
| SCHEMBL978712 | 0.85 | AKR1C3 (0.54) | MAPTRAB9ANPC1SMN1; SMN2HTT | |
| SCHEMBL29461392 | 0.85 | KAT6A (0.51) | KAT6A | |
| SCHEMBL248669 | 0.85 | KAT6A (0.51) | KAT6A | |
| SCHEMBL1619240 | 0.84 | MAPT (0.52) | MAPTRAB9ANPC1SMN1; SMN2EPHX2 | |
| SCHEMBL10912843 | 0.83 | ABL1 (0.42) | MAPTRAB9ALMNAKMT2AMEN1 | |
| SCHEMBL2379221 | 0.83 | MAPT (0.46) | MAPTRAB9ANPC1SMN1; SMN2EPHX2 | |
| SCHEMBL9567403 | 0.83 | KMT2A (0.57) | MAPTRAB9ANPC1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306107-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-12-10 | — | — | US | disclosed |
| US-20090306107-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-12-10 | — | — | US | disclosed |
| US-7148259-B1 | Antibacterial agents | AMGEN INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-20060270651-A1 | ANTIBACTERIAL AGENTS | AMGEN INC. (US) | 2006-11-30 | — | — | US | disclosed |
| US-7053234-B2 | Antibacterial agents | AMGEN INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20040235911-A1 | hydroxyamidines; antibiotic resistance | TULARIK INC. | 2004-11-25 | — | — | US | disclosed |
| US-6780858-B2 | Antibacterial agents | TULARIK INC. | 2004-08-24 | — | — | US | disclosed |
| EP-1246795-A2 | ANTIBACTERIAL AGENTS | Tularik Inc. (US) | 2002-10-09 | — | — | EP | disclosed |
| US-20020045749-A1 | Antibacterial agents | AMGEN INC. | 2002-04-18 | — | — | US | disclosed |
| WO-2001051456-A2 | ANTIBACTERIAL AGENTS | TULARIK INC. (US) | 2001-07-19 | — | — | WO | disclosed |
| US-4832879-A | INTERMEDIATES FOR HERBICIDES | BASF AKTIENGESELLCHAFT (DE) | 1989-05-23 | — | — | US | disclosed |
| US-RE32087-E | 4H-3,1-Benzoxazine derivatives | BASF AKTIENGESELLSCHAFT (DE) | 1986-02-25 | — | — | US | disclosed |
| US-4315766-A | HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1982-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235911-A1 | hydroxyamidines; antibiotic resistance | HNMT, HDHD5, ABCC1 | MAPT 3987/4885RAB9A 941/4885NPC1 2881/4885 |
| US-20060270651-A1 | ANTIBACTERIAL AGENTS | MRPL21, HDHD5, CLPP | MAPT 4113/4885RAB9A 1357/4885NPC1 2994/4885 |
| US-20090306107-A1 | Organic Compounds | BRAF, MAP3K1, RAF1 | MAPT 1483/4885RAB9A 4015/4885NPC1 4110/4885 |
| US-20020045749-A1 | Antibacterial agents | MRPL21, HDHD5, CLPP | MAPT 4113/4885RAB9A 1357/4885NPC1 2994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.